- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06918561
Evaluatie van de werkzaamheid van neothelium FT bij de behandeling van chronische open wonden
Evaluatie van de werkzaamheid van neothelium ft bij de genezing van chronische open wonden: een gerandomiseerde gecontroleerde multicenter -studie
This is a randomized controlled crossover trial evaluating the efficacy of NeoThelium FT in conjunction with standard of care vs. standard of care alone in treating chronic open wounds.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This research will take place across multiple medical centers, where both researchers and participants will know which treatment is being used (open label). Patients who agree to participate and meet the study requirements during screening will be randomly assigned to one of two groups: either standard of care (SOC) alone, or SOC plus NeoThelium FT.
The study includes a crossover component for subjects in the SOC arm. At treatment visit 13 (approximately 84 days post-randomization), SOC arm subjects not having achieved complete wound closure, and still meeting the inclusion/exclusion criteria, are eligible to cross over to the IP arm (SOC plus NeoThelium FT). Crossover subjects will begin IP arm treatment with weekly NeoThelium FT applications for up to 12 treatment visits. The subject will continue follow-up per the original schedule. As this is a post-marketing study, it will gather information regarding the efficacy of treatment while also supporting insurance reimbursement decisions. All subjects will complete two-week screening phase prior to being randomized into a treatment arm. Treatment arms will consist of NeoThelium FT in conjunction with standard of care, vs. standard of care alone. The primary endpoint will be the percentage of target ulcers that achieve complete wound closure within 12 weeks. Secondary endpoints consist of wound percentage area reduction rates and pain assessment.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Angelina Ferguson, DNP
- Telefoonnummer: (985) 629-4013
- E-mail: info@sygnola.com
Studie Contact Back-up
- Naam: Sarah Moore, MBE
- Telefoonnummer: (985) 629-4013
- E-mail: info@sygnola.com
Studie Locaties
-
-
Louisiana
-
Denham Springs, Louisiana, Verenigde Staten, 70726
- Werving
- MedCentris of Denham Springs
-
Hoofdonderzoeker:
- Monique Consoer, NP
-
Contact:
- Tabatha Yent
- E-mail: tabatha.yent@medcentris.com
-
Hammond, Louisiana, Verenigde Staten, 70403
- Werving
- MedCentris of Hammond
-
Hoofdonderzoeker:
- Chris Keaton, NP
-
Contact:
- Chelsea Smith, RN
- E-mail: Chelsea.smith@medcentris.com
-
Contact:
- Melanie Knox, LPN
- E-mail: Melanie.knox@medcentris.com
-
Lafayette, Louisiana, Verenigde Staten, 70507
- Voltooid
- MedCentris of Carencro
-
Leesville, Louisiana, Verenigde Staten, 71146
- Werving
- MedCentris of Leesville
-
Hoofdonderzoeker:
- Stefanie Corley, FNP
-
Contact:
- Brandi Shuff
- E-mail: Brandi.shuff@medcentris.com
-
Many, Louisiana, Verenigde Staten, 71449
- Werving
- MedCentris of Many
-
Hoofdonderzoeker:
- Stefanie Corley, FNP
-
Contact:
- Brandi Shuff
- E-mail: Brandi.Shuff@medcentris.com
-
Marksville, Louisiana, Verenigde Staten, 71351
- Werving
- MedCentris of Marksville
-
Hoofdonderzoeker:
- Averie Rachal, FNP
-
Contact:
- Laura Whittington
- E-mail: Laura.whittington@medcentris.com
-
Metairie, Louisiana, Verenigde Staten, 70001
- Werving
- MedCentris of Metairie
-
Contact:
- Ninya Powell
- E-mail: ninya.powell@medcentris.com
-
Hoofdonderzoeker:
- Sarah Logrande, NP
-
Minden, Louisiana, Verenigde Staten, 71055
- Werving
- MedCentris of Minden
-
Hoofdonderzoeker:
- Taheera Forbes, NP
-
Contact:
- Brianna Thompas
- E-mail: brianna.thompson@medcentris.com
-
Monroe, Louisiana, Verenigde Staten, 71201
- Nog niet aan het werven
- MedCentris of Monroe
-
Hoofdonderzoeker:
- Libbi Trawick, NP
-
Contact:
- Tiffany Dew
- E-mail: Tiffany.dew@medcentris.com
-
Slidell, Louisiana, Verenigde Staten, 70458
- Werving
- MedCentris of Slidell
-
Hoofdonderzoeker:
- Katie Schloegel, FNP
-
Contact:
- Donyille Singletary, RN
- Telefoonnummer: 985-602-1215
- E-mail: Donyille.singletary@medcentris.com
-
-
Mississippi
-
D'Iberville, Mississippi, Verenigde Staten, 39540
- Voltooid
- MedCentris of D'iberville
-
McComb, Mississippi, Verenigde Staten, 39648
- Voltooid
- MedCentris of McComb
-
Natchez, Mississippi, Verenigde Staten, 39120
- Voltooid
- MedCentris of Natchez
-
Southaven, Mississippi, Verenigde Staten, 38671
- Werving
- MedCentris of Southaven
-
Hoofdonderzoeker:
- Carlene McAllister, NP
-
Contact:
- De'Nyia Woods
- E-mail: denyia.woods@medcentris.com
-
-
New York
-
Brooklyn, New York, Verenigde Staten, 11234
- Werving
- Northeast Podiatry Consultant
-
Contact:
- Thomas Hayes
- E-mail: thomas@simonfootandankle.com
-
Hoofdonderzoeker:
- David Simon, DPM, FACFAS
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Male or Female, 18 years of age or older
- Subject has a medical diagnosis of "other" Open wound
- Subject has a chronic open wound present for 4 weeks or greater (documented in medical record), and less than 12 months duration if being treated with continuous SOC
- Subject has a chronic open wound with a historical wound measurement showing less than 25% healing within 14 days prior to screening
- Subject has a chronic open wound with screening wound measurement showing less than 25% healing within 14 days prior to randomization
- Subject has an Open wound without infection or clinically visible exposed bone
- Index wound is a minimum of 0.5cm2 and a maximum of 25cm2 at first treatment visit
- Index ulcer has a maximum depth of 1cm at screening visit 1
- The chronic open wound is treated with offloading therapy, if applicable to location, while standing, sitting, and lying down for 14 days prior to randomization
- Adequate circulation of wounds located below the knee demonstrated by an ABI of >0.7 and <1.3, or TBI of >0.6 within 30 days prior to randomization OR an arterial ultrasound noted with patent circulation and without significant stenosis 90 days prior to randomization.
- Index ulcer is free of infection prior to randomization and during screening phase.
- Index ulcer is free of necrotic debris prior to NeoThelium FT application
- Female subjects of childbearing potential having a negative pregnancy test prior to randomization
- Index ulcer is free of infection prior to randomization and during screening phase noted with the NERDS Assessment. Infection must be adequately treated and controlled prior to randomization.
- Subject is able and willing to follow the protocol requirements
- Subject had signed informed consent
- If 2 or more ulcers are present, the ulcers must be separated by at least 2 cm
Exclusion Criteria:
- Subject with a wound diagnosis of diabetic foot wound, pressure wound, venous leg wound, burn wound, or alternative diagnosis other than "open wound"
- Subject has a known life expectancy of <1 year
- Subject is unable to comply with protocol treatment
- Subject has major uncontrolled medical disorders in the opinion of the investigator, such as serious cardiovascular, renal, liver, pulmonary, autoimmune, palliative care, or inherited blood disorders that may affect wound healing.
- Subject actively being treated for malignant disease or history of malignancy or radiation therapy at the site of wound
- Subject has comorbid conditions that may compromise subject safety in the opinion of the investigator
- Known contraindications to tissue-engineered allograft
- Concurrent participation in alternative clinical trial that involves investigational drug or product interfering with wound treatment and/or healing
- Subject is pregnant or breastfeeding
- Subject with history of immunosuppressant treatment (systemic corticosteroids >10mg daily dose), cytotoxic chemotherapy, or topical steroid application to the wound surface for >2 weeks duration within 30 days prior to randomization; or anticipated use of the above during the course of the study
- Wound previously treated with CAMPs, tissue engineered, or scaffold materials within 30 days prior to randomization
- Open wound with active infection
- Wound depth with visible exposed bone
- HBOT within 14 days prior to randomization
- Revascularization surgery on the index wound leg within 30 days of screening phase
- Index wound suspicious of neoplasm in the opinion of the principal investigator
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: No Intervention: Standard of Care
Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading |
Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading |
|
Experimenteel: Intervention: NeoThelium FT & Standard of Care
Wound cleansing, sharps debridement, NeoThelium FT application, Dressing for moisture balance, Offloading |
NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Complete Wound Closure
Tijdsspanne: 1-12 weeks
|
The primary endpoint will be the percentage of target ulcers that achieve complete wound closure. |
1-12 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage Wound Area Change
Tijdsspanne: 1-12 weeks
|
The percentage change in wound area from TV-1 to TV-13 will be measured weekly using digital photographic planimetry and physical examination. |
1-12 weeks
|
|
Pain Assessment
Tijdsspanne: Day 0, Day 14, Day 35, Day 56, Day 84
|
Change in pain associated with the target ulcer will be assessed using the Numeric Pain Rating Scale at designated time points |
Day 0, Day 14, Day 35, Day 56, Day 84
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Follow-Up Closure
Tijdsspanne: 2 weeks
|
Number of wounds remaining closed during the 2-week follow-up |
2 weeks
|
|
Adverse Events and Serious Adverse Events
Tijdsspanne: Day -14 through 91 days
|
The number and nature of adverse events (AEs) and series adverse events (SAEs) occurring during the study will be tracked and reported. |
Day -14 through 91 days
|
|
Time to Closure
Tijdsspanne: 1-12 weeks
|
Average number of grafts and/or weeks used to achieve wound closure |
1-12 weeks
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie directeur: Angelina Ferguson, DNP, SygNola, LLC
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- HEAL
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .